Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Apexigen, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for cancer treatment, particularly leveraging its proprietary APXi-100 platform. The company operates primarily in the United States, with a pipeline that includes multiple candidates in various stages of clinical trials, which positions it uniquely against competitors with more established products.
Apexigen generates revenue primarily through partnerships and collaborations for clinical trials of its antibody therapies. The company's competitive advantage lies in its proprietary technology platform, which allows for the rapid development of novel treatments, potentially reducing time-to-market and R&D costs.
Progress in clinical trials for APXi-100 and other candidates
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA
Market sentiment towards biotech sector performance
Regulatory changes that could affect drug approval processes
Technological disruption in drug development methodologies
Emergence of new competitors with similar therapeutic approaches
Potential for larger pharmaceutical companies to outpace Apexigen in drug development
Limited cash reserves impacting operational flexibility
Dependence on external funding for clinical trials
low - The biotechnology sector is less sensitive to economic cycles as healthcare spending remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for funding R&D, impacting the company's ability to finance clinical trials.
minimal - Apexigen has low debt levels, reducing its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant volatility, particularly given its recent performance and the inherent risks in biotech.